Robert F. Apple - 08 Jan 2026 Form 4 Insider Report for KAZIA THERAPEUTICS LTD (KZIA)

Reporting relationship: Director
Issuer ticker: KZIA
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2026, 16:57:19 UTC
Prior SEC filing: 26 May 2022
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Bonacorda - Attorney-in-Fact

Key filing fact

Robert F. Apple filed Form 4 for KAZIA THERAPEUTICS LTD (KZIA) on 08 Jul 2026.

Key facts

This page summarizes Robert F. Apple's Form 4 filing for KAZIA THERAPEUTICS LTD (KZIA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2026, 16:57.

Change

Previous filing in this sequence was filed on 26 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001054942 Primary reporting owner

APPLE ROBERT F

Relationship: Director
Address: THREE INTERNATIONAL TOWERS, LEVEL 24, 300 BARANGAROO AVENUE, SYDNEY, NSW, AUSTRALIA
Signature: /s/ Jeffrey Bonacorda - Attorney-in-Fact
Signature date: 08 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KZIA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +75,000
Change %
Price: $0.000000^*
Shares after: 75,000
Date: 08 Jan 2026
Ownership: Direct
Underlying class: ADSs
Underlying amount: 75,000
Exercise price: $6.78
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.